Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q3 2024 Earnings Presentation
15 slides from Autolus Therapeutics's earnings presentation, Nov 12, 2024
Slide 1: Q3 2024 Financial Results and Business Updates
Q3 2024 Financial Results and Business Updates 12 November 2024 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com
Slide 2: Disclaimer
Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,”
Slide 3: Agenda
Agenda • Welcome and Introduction: Olivia Manser, Director, Investor Relations • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO • Q&A: Dr. Christian Itin and Rob Dolski 3
Slide 4: AUCATZYL® now FDA approved
AUCATZYL® now FDA approved Post-period event ✓ AUCATZYL indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) ✓ First chimeric antigen receptor T-cell (CAR T) therapy approved by the FDA with no requirement for a REMS program (Risk Ev
Slide 5: Pillars to drive launch success
Pillars to drive launch success Prioritizing activation of centers Robust and reliable supply Post-approval The Nucleus: Autolus’ state-of-the-art, dedicated purpose-built facility 30 key centers primed for activation covering ~ 60% of r/r B-ALL target population Target vein-to-release time with ~30
Slide 6: Autolus executed to plan in Q3 2024
Autolus executed to plan in Q3 2024 • Obe-cel progressing according to plan – AUCATZYL approved by FDA ahead of PDUFA target action date – Under review by both the EMA and MHRA and submitted to NICE in the UK – Additional data from the FELIX study – Society of Hematologic Oncology meeting in August
Slide 7: Upcoming data at ASH
Upcoming data at ASH • Deep Molecular Remission May Predict Better Outcomes – Abstract 194508 - Oral presentation – Dr. Elias Jabbour - Monday, December 9, 2024; 4:30 PM - 6:00 PM PT • TheClinical Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence – Abstract 201514 – Poster present
Slide 8: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 9: The obe-cel product family and franchise opportunity
The obe-cel product family and franchise opportunity • Optimized CD19 CAR design B-ALL and B-NHL Obe-cel • Potential best-in-class efficacy and safety profile CD19 • Supported by state-of-the-art manufacturing B-cell mediated • Supported by mature FELIX clinical/CMC package autoimmune disease • Dual
Slide 10: Dynamic environment in cell therapy for autoimmune patients
Autoimmune Dynamic environment in cell therapy for autoimmune patients EULAR updates and abstracts for ACR2024 continue to support overall proof of concept/biology in autoimmune disease • Available clinical data is largely based on compassionate use experience with more clinical trial data emerging
Slide 11: Financial Results
Financial Results
Slide 12: Financial summary (unaudited)
Financial summary (unaudited) USD ($’ 000) Q3 2024 Q4 2023 Variance Cash and cash equivalents 657,067 239,566 417,501 USD ($’ 000) Q3 2024 Q3 2023 Variance License revenue - 406 (406) Operating expenses: R&D (40,323) (32,318) (8,005) G&A (27,330) (10,611) (16,719) Loss on disposal of property and eq
Slide 13: Upcoming news flow
Upcoming news flow
Slide 14: Autolus planned news flow
Autolus planned news flow Anticipated Milestone or Data Catalysts Anticipated Timing Obe-cel FELIX data update at ASH 2024 December 2024 Initial data from SLE Phase 1 trial Q1 2025 Initial data from PY01 trial in pediatric ALL 2H 2025 SLE Phase 1 trial presentation at medical conference 2H 2025 Onco
Slide 15: Thank you
Thank you Autolus.com